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Executive summary 
 
• The aim of this project was to review drug-induced deaths data mainly from the general 
mortality registers (GMRs), including the codification practices of drug related deaths 
(DRDs) following the World Health Organisation (WHO) revision of ICD -10 coding 
guidelines related to DRDs. 
 
• The project was divided into three parts and this part, based on aggregated data 
reported by the countries to the EMCDDA, aimed to review coding practices and trends 
in DRDs in countries following the WHO ICD-10 updates. 
 
• In 2002/2003 the World Health Organisation developed a set of ICD-10 updates which 
had a direct impact on the DRDs indicator according to selection B and which were 
implemented in 2006. The EMCDDA protocol was updated accordingly. 
 
• Data on drug related deaths is reported according to selection B as their main source in 
14 countries, according to selection D in 11 countries and according to other specific 
definition in 5 countries. Many countries have established long time trends in the 
reporting of DRDs. 
 
•  Eight countries include non-residents in the data submitted to EMCDDA, while the rest 
do not. 
• Countries follow four major trends in DRDs:  those showing an upward trend (Finland, 
Ireland, Lithuania, Romania, Sweden, Turkey and United Kingdom), those showing a 
downward trend (Czech Republic, Italy, Germany, Poland and Spain, Latvia, Hungary 
(however recent upward trend) Luxembourg and short term downward trend in Cyprus 
and somewhat in Portugal). Those showing a stable trend (Denmark, Netherlands and 
Slovakia) and those showing an upward trend which is now being followed by a 
downward trend (Austria, Belgium, Bulgaria, Croatia, Estonia, France, Malta, Norway).  
 
• When comparing data according to selection B and D, in most countries while 
discrepancies between the two sources may be quite large, however most show the 
same trend direction in deaths over the years. Also for most countries (8/12) the main 
source of data on DRDs, reports more DRDs on average than the other source. 
 
• Reporting according to selection B ICD-10 codes: 
F codes: Most countries for which reporting of ICD codes is possible have relatively low 
levels of F codes. Countries which report more than half of their cases with F codes do not 
have T codes e.g. Austria (100%) and France (53%). 
X41/X61/Y11 and corresponding T code: Reporting of these codes varies according to the 
drug profile of the country, however usually does not account for a large percentage of drug 
related deaths (usually less than 10%). However in countries which cannot report these 
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codes as they do not have T codes, this will lead to a certain degree of under-reporting of 
stimulant related cases.     
X42/X62/Y12 codes: These codes, combined with T-codes capture most of the DRDs and as 
expected they account for the largest percentage of DRDs. 
X44/X64/Y14 codes: These codes are used mainly in countries who have fully implemented 
the ICD updates and the main impact would be on a shift in the coding. However in 
countries with T codes this would not result in any loss in deaths according to selection B. In 
countries like Spain which saw a shift to these codes but do not have T codes, this would 
result in a fall in the number of DRDs according to selection B. Infact Spain now report 
according to another definition which includes X44/X64/Y14 codes.  
 
• Only 5 countries have fully implemented the ICD-10 updates however implementation of 
updates is multi-factorial and coding issues are only part of the problem. 
• A comparison of earlier versus recent ICD-10 coding in countries where this data was 
available showed a decrease in the use of F codes mainly in Belgium and United Kingdom, as 
well as Lithuania (other specific definition). Use of X44 was reported in Belgium, Denmark, 
Malta, Norway and Sweden in their latest available data compared to no countries reporting 
X44 except for Norway previous to the ICD-10 updates. The use of X44 in Poland and Spain 
is not according to EMCDDA definition. 
 
• ICD coding by countries varies and depends on a variety of factors which include availability 
of information on the death certificate, availability of toxicological results, database options 
(e.g. how many codes one is permitted to enter) and coding practices including the uptake 
of WHO revisions. 
 
• A number of recommendations are being proposed to improve the level of accuracy and 
coverage of reporting on drug related deaths. These include training and detailed guidelines 
for coding, inclusion of new T codes for a number of drugs, discussion with WHO regarding 
ICD-11 and its impact on the DRD protocol, inclusion of all T codes into national databases, 
further analysis of drugs coded under T50.9 and other non-specific codes, develop 
methodologies to estimate DRDs in countries with underestimates are large and 
collaboration between EMCDDA, Eurostat and the European Council of Legal Medicine7 
regarding access to autopsy and toxicology reports.  
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1. Introduction  
 
Drug related deaths (DRDs) indicator was established as one of the five epidemiological 
indicators to be monitored on an annual basis by the European Monitoring Centre for Drug 
and Drug Addiction (EMCDDA) in 2001. The DRDs indicator has two components, one 
related to deaths directly caused by illegal drugs and the other component: mortality rate 
amongst problem drug users. This report will be focusing on deaths directly caused by illegal 
drugs. A feasibility study1 carried out in 1990’s which amongst other things established, for 
deaths directly caused by illegal drugs, which ICD codes were to be used for this important 
indicator. The establishment of this indicator was the first of its kind in monitoring drug 
related deaths due to illicit drugs and today 30 European countries provide DRD data to the 
EMCDDA. 
    
As described in the EMCDDA standard protocol version 3.22, there are two main sources of 
data for this indicator, namely the general mortality register (GMR) which report according 
to selection B and are based on mortality data coded using the International Classification of 
Diseases and Related Health Problems (ICD) of the World Health Organisation3 and the 
special register (SR) which report according to selection D and are based on purposely built 
drug registers which often obtain information from multiple sources including mainly 
forensic and police sources.   
 
1.1 Rational 
 
The present study takes place nearly 15 years following the introduction of this indicator 
and aims to review drug-induced deaths data mainly from the GMRs, including the 
codification practices of DRDs following the WHO revision of ICD-10 coding guidelines 
related to DRDs. This is triggered by concerns about systematic underestimation in some 
countries and concerns about differences in coding issues and therefore the impact on 
comparability of data between countries.4 
 
This project which is divided into three parts includes: 
 
a) Reviewing coding practices and trends in DRDs in countries following the WHO ICD-
10 updates; 
b) Reviewing of the Inventory of the national Special Mortality Registries in Europe with 
a focus on information flow to the General Mortality Registries; 
c) Identifying examples of good practice and collaboration between the GMR and SR; 
d) Analysing data on DRDs in a subset of countries to evaluate the use of specific codes 
such as X44/X64/Y14 codes, non specific codes such as R99, X49 and X69 and the use 
or non use of T codes.    
 
This report will focus on reviewing coding practices and trends in DRDs following the WHO 
ICD-10 updates.  
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1.2 ICD-10 codes and the DRD indicator according to selection B 
 
The DRD indicator according to selection B includes cases were the underlying cause of 
death is mental and behavioural disorders due to psychoactive substance use (harmful use, 
dependence, and other mental and behavioural disorders — F-codes) due to a number of 
drugs of abuse, or the underlying cause of death was poisoning (accidental, intentional or of 
undetermined intent — X- and Y-codes) due to a number of drugs of abuse. T-codes (coding 
for substances mentioned in the death certificate) are to be selected in combination with 
the respective X-codes and Y-codes (Table 1).2 Previous to the implementation of this 
indicator by EMCDDA, countries were used to reporting mainly the F, X and Y codes to 
international organisations, as the underlying cause of death and the addition of the T codes 
as requested by the EMCDDA, added another dimension making the indicator more specific, 
accurate and comparable. Though T codes were codes which were included in the ICD 
coding system and should have always been used, they are not uniformly used or collected 
by all countries, also because this requires additional information to be available to 
countries to be able to code at this level.  However for those countries who use these codes 
and have this information the EMCDDA helped to develop an indicator that was more 
accurate and comparable then just looking at the main underlying cause of death. 
 
Table 1: EMCDDA protocol for reporting drds according to selection B2 
  
Underlying cause of death Selected ICD-10 codes 
Disorders F11-F12, F14-F16, F19 
Accidental poisoning X421, X412 
Intentional poisoning X621, X612 
Poisoning undetermined intent Y121, Y112 
Exposure to other and unspecified drugs X443,X643, Y143 
1 in combination with T codes: T40.0-T40.9 
2 in combination with T code: T43.6 
3 in combination with T codes: T40.0-T40.9 or T43.6 
 
 
1.3 ICD-10 updates 
 
The World Health Organisation provides new updates to the current ICD version on a yearly 
basis. In 2002/2003 a set of updates were developed which had a direct impact on the DRDs 
indicator5.    
 
 
The 3 main ICD updates in DRDs in 2002/2003 were: 
 
1. Giving priority to codes X and Y over F when there was a poisoning;  
2. In selecting the underlying cause of death when no component is specified as the main 
cause of death, clarification should be sought from the certifier. When no such 
clarification can be obtained, code combinations of alcohol with a drug to the drug. For 
other multi-drug combination deaths, code to the appropriate category for “Other” 
combination. 
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3. Identifying the most dangerous drug: A priority rule for identification of the most 
dangerous substance (and respective T code) if not identified by certifier and if no 
appropriate combination category is available (see appendix 1 for hierarchical order). 
 
 
The first update implies that countries who implement these updates should see a shift in 
coding from F codes to X and Y codes as the update gives priority to these codes. This will be 
seen especially in countries which used F codes frequently but have additional information 
which would allow them to code to X and Y codes.  
The second update refers to multi-drug combination when no component is specified as the 
main cause of death. In cases where the drugs are from different categories and it is not 
possible to seek clarification from the certifier as to the main cause of death X44 or X64 or 
Y14 should be used. X44 refers to ‘Accidental poisoning by and exposure to other and 
unspecified drugs, medicaments and biological substances’.3 In countries who 
implemented this update one should except to see a shift in cases previously coded as F 
codes to X44 codes or from X42 or X41 codes to X44 codes, especially if previous to the 
update this code was used solely for ‘other and unspecified drugs, medicaments and 
biological substances’ and not for multi-drug combination. 
The third update created a hierarchy from the most dangerous to the least dangerous drug; 
however this should only be coded by countries following updates one and two.   This may 
allow identifying some additional relevant DRD cases that previously might have been 
unrecognised (e.g. deaths due to combination of substances where it was not possible to 
know the main substance and were possibly coded as T50.9 (Other and unspecified drugs, 
medicaments and biological substances) and therefore not selected by selection B.  
However these updates can only be implemented fully in countries who also code using T 
codes.   
 
 
In order to accommodate for these updates, EMCDDA updated its protocol2 and included 
codes X44, X64 and Y14 (in combination with the relevant T-Codes). However these codes 
were only included for those countries where coding using T codes was done. The reasoning 
behind this is that X44, X64 and Y14 are very non specific and could include in particular 
medicines and biological substances which are not collected in the DRD indicator. In cases 
where no T codes are stated this would be over-inclusive. In countries that do not have T 
codes and therefore only report F, X42/X62/Y12 codes to EMCCDA, it is not known whether 
this ICD update resulted in a shift of DRDs from F and X42 codes to X44 codes which would 
result in loss of cases reported to EMCDDA.   
 
Previous work carried out by the EMCDDA and presented at the 2015 September 21-22 
Annual expert meeting4 has shown how and to which extent coding of drug related deaths 
varies between countries, and the adoption of the ICD-updates in DRDs of 2002/03 (to be 
implemented in 2006 and as described in the EMCDDA DRD protocol2) has not been uniform 
across countries.  
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2. Aims and objectives 
 
2.1 Main Aim 
 
The overall aim of this part of the project is, based on aggregated data reported by the 
countries to the EMCDDA, to analyse the codification practices and the changes in the codes 
of the reported cases, in the different countries before and following the WHO updates in 
2002/2003. 
 
The analyses of the national figures will be interpreted in view of replies given by countries 
to the questionnaire on coding done by EMCCDA in 2015 and presented at the 2015 
September 21-22 Annual expert meeting.4 
 
 
2.2 Objectives 
 
The objectives of this part of the study will be to: 
 
 
1. Analyse overall trends since 2000 in the DRDs numbers and breakdowns by code, for the 
country’s main source of data.  
 
2. Report on the level of agreement between GMR and SR numbers and trends in the 
various countries. 
 
3. Analyse the codes and trends (before and after adoption of WHO guidelines) of the 
respective contribution of each main code (F, the ‘classical’ X/Y- X41,X42, X61,X62, Y11, 
Y12 – and the ‘new’ codes X44, X64/Y14) to the total amount of cases in Selection B in 
the countries where this is possible. 
 
4. Interpret the ICD codes breakdown and trends at country level based on country replies 
to EMCDDA questionnaire in 2015. 
 
3.  Methodology 
 
 
The main sources of information used to draw up this report are: 
 
• EMCDDA website, statistical bulletin 2016, section on data and statistics: overdose 
deaths;6 
• Data extracted from EMCDDA database of previous years; 
• Replies to questionnaires on coding practices reported to EMCDDA  in 2015  
 
Analysis of overall trends as well as trends according to selection B and D and finally by ICD-
10 codes as per EMCDDA protocol for selection B was undertaken.   
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4. Main Findings 
 
4.1 Data availability 
 
Data on drug related deaths according to selection B, selection D or other selection varies 
among the EU 28, Norway and Turkey that provide data to EMCDDA, however  as seen in 
table 1 below, most countries have established long time trends in DRDs data. Data on drug 
related deaths is reported according to selection B as their main source in 14 countries, 
according to selection D in 11 countries and according to other specific definition in 5 
countries. Also eight countries include non-residents in the data submitted to EMCDDA, 
while the rest do not.  
 
Table 2: Availability of DRD data according to selection B, selection D or other specific definition. 
Source EMCDDA Statistical bulletin 2016. DRD Key indicator6 
 
Country Data availability 
according to 
Selection B 
Data availability 
according to 
Selection D 
Data availability 
according to national 
definition if different 
from sel B or D  
Austria 1998-2014 1995-2014 Same as selection D 
Belgium 1995-2012 - Same as selection D 
Bulgaria* 1995-2014 2001-2014 Same as selection B 
Croatia 1995-2014 - Same as selection B 
Cyprus - 2004-2014 Same as selection D 
Czech Republic 
1999-2014 1998-2011 National definition is 
broader than 
selection D 
Denmark 1995-2001; 2005-
2013 
1997; 2001-2014 Same as selection B 
Estonia 1997-2014 - Same as selection B 
Finland 1996-2014 1995-2013 Same as selection B 
France 
1995-2012 1996-2002 Same as selection B 
but excludes opioid 
medications used as 
pain killers 
Germany 
1995-2013 - Other specific 
definition (1995-
2014) 
Greece 
 1995-2014 
(except 2012) 
Different (in 
agreement with 
selection D up to 
2002) 
Hungary 2004-2014 1996-2014 
(except 2002) 
Same as selection D 
Ireland 1995-2004 1998-2013 Same as selection D 
however for local 
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use may include a 
wider selection of 
cases 
Italy 1995-2003; 2006-
2012 
1995-2013 Same as selection D 
Latvia 1996-2014 1999-2014 Same as selection B 
Lithuania 
 1999-2003 Other specific 
definition (1995-
2014) 
Luxembourg 
1998-2014 1995-2004 Other specific 
definition (1995-
2014) 
Malta 1995-2014 1995-2004 Same as selection B 
Netherlands 1995-2014 - Same as selection B 
Norway 1996-2013 1995-2009 Same as selection B 
since 2003 
Poland 
- - Other specific 
definition (1995-
2013) 
Portugal 2002-2013 2008-2014 Same as selection D 
Romania - 2001-2014 Same as selection D 
Slovakia - 2004-2014 Same as selection D 
Slovenia 1997-2014 - Same as selection B 
Spain 
1999-2013 (except 
2001) 
1995-2013 Other specific 
definition (1995-
2013) 
Sweden 1995-2014 - Same as selection B 
Turkey - 2005-2014 Same as selection D 
United Kingdom* 2004-2013  Same as selection B 
* data from these countries was not always according to selection B 
 
 
4.2 Trends in DRDs 
 
Comparing mortality rates from DRDs may be difficult due to some differences in reporting 
and in the coverage between countries; however trend analysis may be more informative. 
Trend analysis was performed from the year 2000 to the latest year available in those 
countries for which the data was available. The trend analysis was based on the countries’ 
main source of data.  
 
Countries fall into four major groups: 
 
a) Countries which showed an increasing trend but are now experiencing a downward 
trend. These countries include: Austria, Belgium, Bulgaria, Croatia, Estonia, France, 
Malta and Norway.  
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Figure 1: Trends in DRDs in countries showing an upward followed by downward trend 
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b) Countries showing a long term downward trend: Czech Republic, Italy, Germany, 
Poland and Spain. In Latvia a small downward trend was followed by a stable trend 
(although it should be noted that DRD data are notoriously underestimated there), 
while in Hungary a downward trend was followed by an upward trend. Luxembourg 
is mainly showing a downward trend. Short term trends showing a downward trend 
were also observed in Cyprus and somewhat in Portugal however this was difficult to 
interpret, due to small number in Cyprus, but also to the changes in definition in 
Portugal. 
 
Figure 2: Trends in DRDs in countries showing a long term downward trend 
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c) Countries showing a long term stable trend: Denmark, Netherlands and Slovakia. 
 
Figure 3: Trends in DRDs in countries showing a stable trend 
 
 
 
 
 
 
d) Countries showing an upward trend: Finland, Ireland, Lithuania, Romania, Sweden, 
Turkey. United Kingdom is not showing a stable upward trend though.    
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Figure 4: Trends in DRDs in countries showing an upward trend 
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4.3 Discrepancies between selection B, selection D and/or national definition 
 
In countries which are able to provide data according to selection B,  selection D and or 
national definition, this often represent different sources of information and also coverage, 
which lead to discrepancies in the figures between the sources as shown in table 3 below. 
Average percentage difference between the main source of data and the other source of 
data from the year 2000 to when last available was calculated for those countries which 
provided data on DRDs from selection B, selection D and/or national definition for some 
years. In most countries while discrepancies between the sources may be quite large, 
however most show the same trend direction in deaths over the years with the exception of 
Czech Republic. Also for most countries (8/12) the main source of data on DRDs reports 
more DRDs on average than the other source (Table 3 and Figure 5).      
 
 
 
 
Table 3: Discrepancies between main source of data and other source for reporting DRDs 
for the latest year with available data, and trend direction between 2000 and 2016. 
Source EMCDDA Statistical bulletin 2016 DRD Key indicator6 
 
 
Country 
Difference 
between main 
source and 
other source 
Average % 
difference 
between 
sources 
Trend direction in 
sel B, sel D and/or 
national def   
Austria less 9.1 same 
Bulgaria less 15.6 mostly same 
Czech Republic more 56.3 different 
Denmark more 21 same 
Finland more 31.1 same 
Hungary less 22.2 same 
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Italy more 19.4 same 
Latvia less 100.6 same 
Malta more 10.6 same 
Norway more 25.1 same 
Portugal more 53.3 same 
Spain more 48.0 same 
 
 
Figure 5: Trends in DRDs according to selection B, selection D and/or national definition    
 
 
 
 
 
19 
 
 
 
 
 
 
 
 
 
20 
 
 
 
 
 
 
 
21 
 
  
 
 
 
 
 
22 
 
 
 
 
4.4 Analysis by ICD code 
 
 
The EMCDDA definition of a DRD according to selection B is as per protocol described in 
table 1 previously and its full application implies the availability of T-codes, as these need to 
be combined with the respective X or Y codes. Codes X44, X64 and Y14 have been added 
since WHO ICD-10 update in 2006. In countries which do not have T-codes, codes X41, X61, 
Y11, X44, X64 and Y14 should not be reported according to selection B. The figures below 
describe trends in ICD-10 codes used to report DRDs according to selection B in a number of 
countries were this data was available according to EMCDDA database.   
 
 
Figure 6: Trends in DRDs according to ICD-10 codes used to report DRDs according to 
selection B in various countries 
 
 
  
23 
 
 
 
 
 
 
 
24 
 
 
 
 
 
 
 
25 
 
 
 
 
 
 
 
 
26 
 
 
 
 
 
 
 
 
27 
 
 
 
 
 
 
28 
 
 
In the country graphs described above, the majority of deaths are found in X42/X62/Y12 
code in most countries. The use of F codes is limited in most countries except for France, 
Germany, Belgium and Spain. Often this is related to the unavailability of T codes. It is 
difficult to interpret if the ICD-10 updates to be implemented in 2006 had any impact on 
coding practices due to the unavailability of long term trends. However in most countries 
there was minor or no impact and the use of X44/X64/Y14 is very limited. The only 
exception is Spain which saw a reduction in X42 and F codes. There was a corresponding 
increase in X44 code, however since T codes are not available, this is not included in 
selection B, creating an artificial fall in the number of DRDs according to selection B.       
 
 
4.5 Latest available DRD data in various countries by ICD-10 breakdown  
 
Table 4 below describes the latest available data according to ICD-10 codes used for 
countries reporting according to selection B or other specified definition. Countries which 
are shaded do not use or no longer use selection B as the primary source of data extraction 
and national definition.  
 
Table 4: Percentage of DRDs according to ICD-10 code. Source EMCDDA Statistical bulletin 2016. 
DRD Key indicator 
 
    % of deaths in the different ICD groups 
ICD code groups 
Country (latest 
year with available 
data)  Definition 
F codes X41, X61, Y11 
X42, X62, 
Y12 
X44, X64, 
Y14 
Austria (2013) Selection B 
100.0 
(n=139)       
Belgium (2012) Selection B 27.8 (n=20) 4.2 (n=3) 
62.5 
(n=45) 5.6 (n=4) 
Bulgaria (2014) Selection B 0.0 0.0 
100.0 
(n=15) 0.0 
Croatia (2014) Selection B 
18.6 
(n=11) 1.7 (n=1) 
79.7 
(n=47) 0.0 
Denmark (2013) Selection B 
11.3 
(n=25) 0.9(n=2) 
44.6 
(n=99) 43.2(96) 
Estonia (2014) Selection B 0.0 6.1 (n=6) 
93.9 
(n=92) 0.0 
Finland (2014) Selection B 
13.1 
(n=23) 4.0 (n=7) 
83.0 
(n=146) 0.0 
France (2012) Selection B 
53.0 
(n=140) 0.0 
47.0 
(n=124) 0.0 
Latvia (2014) Selection B 0.0 13.3 (n=2) 
86.7 
(n=13) 0.0 
Lithuania (2014) 
Other 
(Specific 
Definition) 
1.1 
(n=1) 0.0 
98.9 
(n=86) 0.0 
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F codes 
 
According to the ICD updates priority should be given to X or a Y code over F codes when 
there is poisoning, therefore we should be seeing less of this code. Most countries for which 
reporting of ICD codes is possible (Table 4) have relatively low levels of F codes. Countries 
which report more than half of their cases with F codes do not have T codes e.g. Austria 
(100% of the cases coded F)  and France (53%). In the case of Austria GMR is not their main 
source of information on DRDs.    
 
 
 
X41, X61, Y11 coding 
 
These codes, combined with T43.6 capture only stimulant related cases, and therefore are 
relatively marginal. According to the EMCDDA protocol in countries which do not have T 
codes, these codes should not be reported as otherwise it would lead to other drugs not in 
the EMCDDA definition being included in particular antidepressants and neuroleptics. In 
countries who do report these codes the highest percentage being reported is for Latvia 
where these codes account for 13.3% of DRDs, however the actual number is small (n=2) 
(bearing in mind the limitations of the data in Latvia). However this varies according to the 
drug profile of the country. However in countries which cannot report these codes as they 
do not have T codes, this will lead to a certain degree of under-reporting of stimulant 
related cases.     
 
 
 
 
 
Malta (2014) Selection B 0.0 0.0 50.0 (n=1) 50.0 (n=1) 
Netherlands (2014) Selection B 
21.1 
(n=26) 
11.4 
(n=14) 
67.5 
(n=83)_ 0.0 
Norway (2013) Selection B 
10.7 
(n=25) 6.4 (n=15) 
70.1 
(n=164) 12.8 (n=30) 
Poland (2013) 
Other 
(Specific 
Definition) 
2.0 
(n=5) 0.0 (n=0) 
48.6 
(n=120) 49.4 (n=122) 
Slovenia (2014) Selection B 0.0 3.6 (n=1) 
96.4 
(n=27) 0.0 
Spain (2013) 
Other 
(Specific 
Definition) 
5.5 
(n=22) 0.0 
22.8 
(n=92) 71.7 (n=289) 
Sweden (2014) Selection B 
3.6 
(n=22) 6.2 (n=38) 
47.9 
(n=292) 42.2 (n=257) 
United Kingdom 
(2013) Selection B 
5.8 
(n=142) 
5.8 
(n=141) 
77.7 
(n=1902) 10.8 (n=264) 
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X42, X62, Y12 coding 
 
These codes, combined with T-codes for other main drugs (in particular heroin) capture 
most of the DRD and as expected they account for the largest percentage of DRDs. However 
in some countries this accounts for less than 50% of all DRDs. The main reasons for this are 
that either due to the absence or low levels of T codes available, some countries report 
more F codes as previously described or in countries where there is relatively high levels of 
X44 codes such as Denmark, Malta, Sweden which have implemented ICD-10 updates and  
Spain and Poland which report according to another definition.  
 
 
X44, X64, Y14 coding 
 
In countries who have fully implemented the ICD updates, the main impact would be on a 
shift in the coding. In countries with T codes this would not result in any loss in deaths 
according to selection B. However few countries have fully implemented the ICD-10 
updates.  
In countries like Spain which saw a shift to these codes but do not have T codes, this would 
result in a fall in the number of DRDs according to selection B. Infact Spain now report 
according to another definition which includes X44/X64/Y14 codes.  
   
The main reasons stated by countries who answered the EMCDDA questionnaire sent and 
presented in 20154 as to why ICD-10 updates were not implemented or only partially 
implemented are: 
 
1) T codes are not always available. When a high percentage of death certificates do 
not have T codes, implementation of ICD updates is very limited, as is, the full 
application of the protocol. 
2) Interpretation of X44 as ‘substances listed under X44’only. 
3) Only one T code included in database, therefore if there are multiple drugs 
responsible for the death, this information is lost. 
4) T code only coded if it is the second cause of death. 
 
 
Therefore the implementation or otherwise of ICD updates is multi-factorial and coding 
issues are only part of the problem. The main areas where improvement would be relatively 
simple to implement is in the training and encouragement to include all T codes in countries 
when these are available.   
 
There are five countries who have fully implemented the ICD-10 updates as per table 5 
below.  The use of X44 varies between countries and again in countries which do not have T 
codes, X44 is not to be reported according to EMCDDA protocol. The shaded countries do 
not use the GMR as their main source of information for DRDs. 
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Table 5: Implementation or otherwise of ICD-10 updates according to countries response to 
EMCDDA 2015 questionnaire4 
 
   
 Country 
Implementation 
of ICD-10 
updates Comments 
Austria No No T codes available 
Belgium Partial Lack of T codes in one region 
Bulgaria No   
Croatia Full X44 code never used however for DRD 
Czech Republic Partial 
GMR not main reporting system and lack of T 
codes 
Denmark Full   
Estonia Partial 
Different interpretation of X44 i.e. ‘substances 
listed under X44’  
Finland Partial 
Different interpretation of X44 i.e.’ Perhaps 
unknown toxicology, but in Finland forensic 
toxicological registry can normally identify all 
drugs’ 
France Partial No T codes available 
Germany Partial Low levels of T codes 
Italy Partial 
GMR not main reporting system and different 
interpretation to X44 
Ireland Partial 
GMR not main reporting system and limited 
number of T codes entered on computer system 
Latvia Partial 
Different interpretation of X44 i.e. ‘The code X44 
is set for cases with unknown toxicology but not 
for cases related to DRD’ 
Lithuania Partial 
Different interpretation of X44 i.e. “Accidental 
poisoning by and exposure to other and 
unspecified drugs, medicaments and biological 
substances” 
Malta Full   
Netherlands Partial No feedback on X44 
Norway Full   
Portugal Partial 
GMR not main reporting system and different 
interpretation to X44 
Slovenia No only one T code included, no ICD 10 updates  
Spain Partial 
GMR not main reporting system. No T codes 
available 
Sweden Full   
United Kingdom Partial 
only refer to the second cause of death to 
identify a T code 
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4.6 Loss of reporting of drug related deaths according to EMCDDA protocol 
 
The use of T codes in the EMCDDA definition adds specificity and accuracy when reporting 
on DRDs. Not specifying the substances would lead to considerable overestimation as the 
underlying cause only would yield cases related to e.g. alcohol and medicines. The current 
selection B is the balanced choice between specificity and sensitivity, which was done by the 
European experts and the EMCDDA, and is currently explained in the DRD protocol. 
However it also has its limitations. In countries which do not have T codes the EMCDDA 
protocol does not include X41, X61, Y11, X44, X64 and Y14 codes due to the over inclusive 
nature of these codes. This means that countries who do not report these codes would have 
a certain degree of under-reporting. In the replies to the EMCDDA questionnaire done in 
20154, a number of countries stated that DRDs were under-reported. Reasons were related 
to both certification and codification issues.  
Other codification issues not mentioned above include: 
 
1) T50.9 (i.e. Other and unspecified drugs, medicaments and biological substances) 
used to code cases where no T codes are available and in poly-drug cases. 
2) X42/X62/Y12/T43.9 used to code unspecified description “intoxication by drugs” on 
the death certificate. 
3) T42.6 used to code drugs like Pregabalin as a prescription drug of new relevance for 
DRD may be difficult for classification;  
4) No specific T codes for new synthetic substances.  
5) T43.6 used for substances not applicable to any specific T-code. 
 
The above mentioned codification issues effect to a certain degree which varies between 
countries, the amount of under-reporting, as the codes mentioned in point 1-4 above are 
not included in the EMCDDA protocol. The use of unspecified X and Y codes to code drug 
related deaths which are non specific may also include X49, X69 and Y19.  
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4.7 Comparisons during earlier versus later DRDs data in ICD codes used, 
impact of WHO update 
 
In countries reporting according to selection B (table 6), (countries which are not  
shaded) a comparison was made of the codes used to report DRDs as percentages, in the 
earlier years compared to the most recent data available. It was not possible to use years 
prior to the WHO ICD-10 updates in some countries as this information was not available. 
Changes in the percentages in the different ICD groups depends both on certification and 
codification issues. However when comparing percentages in the earlier to later period few 
changes seemed to have taken place vis a vis the WHO ICD updates.  
A decrease in the use of F codes was seen mainly in Belgium and United Kingdom, as well as 
Lithuania (other specific definition)   however in other countries which report low levels of F 
codes, this was also so in the earlier period (however as stated previously data before ICD-
10 updates was not always available in some countries). Use of X44 was reported in 
Belgium, Denmark, Malta, Norway and Sweden in their latest available data compared to no 
countries reporting X44 except for Norway previous to the ICD-10 updates. 
The use of X44 Poland and Spain is not according to EMCDDA definition, as in Spain  X44 is 
used for accidental poisonings due to exposure to drugs and is very commonly used to 
codify deaths due to “overdose.”The GMR of Spain doesn´t not include toxicology 
information, so T codes are not included. Poland also does not have T codes. 
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Table 6: Comparisons of ICD codes used, impact of WHO update 
(*data for the UK has been updated recently and figures below may need to be updated) 
 
ICD code groups
F codes
X41, 
X61, 
Y11
X42, 
X62, 
Y12
X44, 
X64, 
Y14 ICD code groups Definition
F codes
X41, 
X61, 
Y11
X42, 
X62, Y12
X44, 
X64, Y14
Belgium (2005)
45.7 
(n=48)
0.0
54.3 
(n=57)
0.0 Belgium (2012) Selection B
27.8 
(n=20)
4.2 (n=3)
62.5 
(n=45)
5.6 (n=4)
Bulgaria (2006)
0.0
20.7 
(n=6)
79.3 
(n=23)
0.0
Bulgaria (2014) Selection B
0.0 0.0
100 
(n=15)
0.0
Croatia (2008)
4.6 
(n=4)
4.6 
(n=4)
90.8 
(n=79)
0.0
Croatia (2014) Selection B
18.6 
(n=11)
1.7 (n=1)
79.7 
(n=47)
0.0
Denmark (2005)
17.4 
(n=36)
0.5 
(n=1)
82.1 
(n=170)
0.0
Denmark (2013) Selection B
11.3 
(n=25)
0.9 (n=2)
44.6 
(n=99)
43.2 
(n=96)
Estonia (2006)
0.0
4.4 
(n=3)
95.6 
(n=65)
0.0
Estonia (2014) Selection B
0.0 6.1 (n=6)
93.9 
(n=92)
0.0
Finland (2006)
2.9 
(n=4)
8.7 
(n=12)
88.4 
(n=122)
0.0
Finland (2014) Selection B
13.1(n=2
3)
4.0 (n=7)
83.0 
(n=146)
0.0
France (2006)
60.3 
(n=184)
0.0
39.7 
(n=121)
0.0
France (2012) Selection B
53.0 
(n=140)
0.0
47.0 
(n=124)
0.0
Latvia (2006)
0.0
11.8 
(n=2)
88.2 
(n=15)
0.0
Latvia (2014) Selection B
0.0
13.3 
(n=2)
86.7 
(n=13)
0.0
Lithuania (2006)
28.6 
(n=18)
1.6 
(n=1)
69.8 
(n=44)
0.0
Lithuania (2014) Other 
1.1 (n=1) 0.0
98.9 
(n=86)
0.0
Malta (2006) 0.0 0.0 85.7 14.3 Malta (2014) Selection B 0.0 0.0 50 (n=1) 50 (n=1)
Netherlands (2006)
14.3 
(n=16)
3.6 
(n=4)
82.1 
(n=92)
0.0
Netherlands (2014) Selection B
21.1 
(n=26)
11.4 
(n=14)
67.5 
(n=83)
0.0
Norway (2005)
11.1 
(n=26)
5.1 
(n=12)
76.1 
(n=178)
7.7 
(n=18) Norway (2013) Selection B
10.7 
(n=25)
6.4 
(n=15)
70.1 
(n=164)
12.8 
(n=30)
Poland Poland (2013) Other 2.0 (n=5) 0.0 48.6 49.4 
Slovenia (2005)
5.6 
(n=2)
0.0
94.4 
(n=34)
0.0
Slovenia (2014) Selection B
0.0 3.6 (n=1)
96.4 
(n=27)
0.0
Spain Spain (2013) Other 5.5 0.0 22.8 71.7 
Sweden Sweden (2014) Selection B 3.6 6.2 47.9 42.2 
United Kingdom* (2007)
54.2 
(n=1068
)
2.6 
(n=52)
42.3 
(n=835)
0.9 
(n=17)
United Kingdom* (2013) Selection B
5.8 (n=142)5.8 (n=141)7.7 (n=190210.8 (n=264)
% of deaths in the ICD groups% of deaths in the ICD 
 
 
 
5. Discussion and Recommendations 
 
Efforts to improve accuracy and coverage of DRDs are dependent on both certification and 
codification processes. Having a protocol in place as that developed by the EMCDDA is 
important for harmonisation of data extraction. Countries which have access to multiple 
sources of information especially those able to access autopsy and toxicology reports helps 
greatly improves coverage and accuracy. In those countries were under-reporting of DRDs is 
considered to be high, greater efforts by national focal points is needed to bring together 
key stakeholders with the aim of improving coverage, completeness and sensitivity of DRDs. 
 
ICD updates by WHO in 2002/2003 may allow identification of some additional relevant DRD 
cases that previously might have been unrecognised under X44 or X49 codes. However as 
described in previous sections of this document updates were not universally adopted by all 
countries for a number of reasons, one of the main being the absence or insufficient use of 
codes to specify the substances related to the deaths (i.e. the T-codes).  
 
ICD coding by countries varies and depends on a variety of factors which include availability 
of information on the death certificate, availability of toxicological results, database options 
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(e.g. how many codes one is permitted to enter) and coding practices including the uptake 
of WHO revisions. 
 
The availability or otherwise of T codes often determines whether or not WHO updates can 
be implemented. Also in countries who only have one T code in their database this limits the 
possibility of implementing ICD updates.    
 
 
In countries which provide DRD data from the GMR and the SR it is often the case that one 
source provides a more comprehensive data set than the other. For most countries the main 
source of data on DRDs reports more cases on average than the other source. However this 
is not always so and greater cooperation between the two sources needs to be developed. 
In countries where data protection laws permit it, linkage between SR and GMR should be 
done where this is possible.   
 
A number of recommendations regarding guidelines to ICD-1O coding were described in the 
EMCDDA scientific report CT.00.RTX.227 of 2002 and have been implemented by the WHO 
through the ICD-10 updates.  Also this report created a number of methodologies which can 
be used by countries to estimate the burden of drug related deaths in a country depending 
on what is feasible in a particular country. Estimation of the direct number of DRDs is done 
in Spain, and such or similar procedure may be necessary in other countries whose register 
underestimates DRDs to a substantial extent. Other estimates may be made based on 
overdose rates in cohort studies and POU estimates. 
 
Based on the findings in this report and on previous studies the following 
recommendations are being proposed: 
 
• Provision of guidelines/training for coding of DRDs especially when new updates are to 
be implemented.  
• Discussion with WHO regarding T codes for new drugs. 
• Discussion with WHO regarding ICD-11 and any foreseen impact on the DRD protocol. 
• Greater efforts to include all T codes rather just one T code in the country databases. 
• In those countries when only one T code can be inputted this should be according what 
the certifier thinks is the most important drug or if no indication given, this should follow 
the ICD-1O priority guidelines; 
•  Further analysis of drugs coded under T50.9 and other non-specific codes.   
• Develop methodologies to estimate DRDs in countries with underestimates allowing 
more accurate data to be compared between countries. 
•  Collaboration between EMCDDA, Eurostat and the European Council of Legal Medicine7 
regarding access to autopsy and toxicology reports.  
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Annex 1 
 
Identifying the most danagerous drug according to ICD 10 2002/2003 updates5 
 
To provide useful statistics on multiple drug deaths, it is of utmost importance that the most 
dangerous drug is identifiable in addition to the underlying cause (see also Nature of injury, pp. 
86–87). When selecting the code for the most dangerous drug, apply the following instructions. 
If one component of the combination is specified as the cause of death, code to that 
component. If no single component is indicated as the cause of death, code combinations of 
alcohol with a drug to the drug. When the classification provides a specific category for a 
combination of drugs, e.g. mixed antiepileptics (T42.5), code to that category. If no appropriate 
combination category is available, select the main injury code in the following order of priority: 
1. Opioids (T40.0-T40.2): Combinations including opioids classifiable to more than 
one fourth-character subcategory in T40.0-T40.2: Code to T40.2 
2. Cocaine (T40.5) 
3. Psychostimulants with abuse potential (T43.6). Includes: Amphetamine and 
derivates 
4. Synthetic narcotics and other and unspecified narcotics (T40.3-T40.4, T40.6) 
Combinations including synthetic narcotics classifiable to more than one fourth-character 
subcategory in T40.3-T40.4: Code to T40.4 
Combinations including synthetic narcotics classifiable to more than one fourth-character 
subcategory in T40.3-T40.4 with other and unspecified narcotics classifiable to T40.6: Code to 
T40.6 
5. Antidepressants (T43.0-T43.2): Combinations including antidepressants 
classifiable to more than one fourth-character subcategory in T43.0-T43.2: Code 
to T43.2 
6. Non-opioid analgesics (T39.-): Combinations including non-opioid analgesics 
classifiable to more than one fourth-character subcategory in T39.0-T39.4: Code 
to T39.8 
7. Drugs and substances not listed above: If the death certificate reports more 
than one such drug, code to the first mentioned.  
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